CDNAのチャート
CDNAの企業情報
| symbol | CDNA |
|---|---|
| 会社名 | CareDx Inc （ケアディ―エックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 CareDx（CareDx Inc.）は市場を開発し、心臓移植レシピエントのための診断監視ソリューションの提供を通じて、患者の寿命を通してパーソナライズされた治療の意思決定を行うために、医者を支援する商業段階の会社である。同社のAlloMap心臓移植分子検査は、急性細胞性拒絶反応のための心臓移植レシピエントを監視するために使用される血液ベースのテストである。AlloMapは国際心臓と肺移植協会（ISHLT）の非乳児の心臓移植拒絶反応の監視のための患者ケア・ガイドラインの中に、勧められる非侵襲的方法である。同社は臓器移植レシピエントのための診断監視テスト・ソリューションを開発・提供する。その商用テスト・ソリューションAlloMapは、拒絶反応のリスクが低い心臓移植レシピエントの識別を支援するために、遺伝子発現技術を使用する。 ケアディ―エックスは、米国の医療機器ソリュ―ションの開発会社。臨床医が患者の生涯を通じて個々に応じた治療の意思決定を支援するために、心臓移植患者の診断・監視するソリュ―ションを開発、マ―ケティング、供給する。同社が最初に商品化した製品「AlloMap」は、心臓移植患者の急性細胞性拒絶を監視するために使われる血液ベ―スの検査製品である。 CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. |
| 本社所在地 | 3260 Bayshore Boulevard Brisbane CA 94005 USA |
| 代表者氏名 | Michael D. Goldberg マイケル・D・ゴールドバーグ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 415-287-2300 |
| 設立年月日 | 36130 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 179人 |
| url | www.caredx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cdna |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.63200 |
| 終値（lastsale） | 24.19 |
| 時価総額（marketcap） | 879212739.56 |
| 時価総額 | 時価総額（百万ドル） 892.29740 |
| 売上高 | 売上高（百万ドル） 56.57000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 889.52740 |
| 当期純利益 | 当期純利益（百万ドル） 3.53000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 CareDx Inc revenues increased 35% to $31.9M. Net loss increased from $9.5M to $23M. Revenues reflect Post-Transplant segment increase of 50% to $24.9M North America segment increase of 47% to $27.3M. Higher net loss reflects Pre-Transplant segment loss increase of 2% to $4.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.45 to -$0.70. |
CDNAのテクニカル分析
CDNAのニュース
JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice 2023/01/26 12:01:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monito
Can you still get a good price for CareDx Inc (CDNA) Shares at this point? 2023/01/25 15:48:00 US Post News
A share of CareDx Inc (NASDAQ:CDNA) closed at $15.16 per share on Tuesday, up from $15.05 day before. While CareDx Inc has overperformed by 0.73%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CDNA fell by -59.06%, with highs and lows ranging from $46.88 to $10.50, […]
CareDx guides for record Q4 revenue 2023/01/09 13:55:49 Seeking Alpha
Precision medicine solutions company CareDx (CDNA) expects record revenues of $81.9M to $82.2M for fourth quarter of 2022, representing year-over-year growth of approximately 4%
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022 2023/01/09 12:00:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter Highlights Delivered record revenues; expected to be between $81.9 million to $82.2 million, representing year-over-year gro
How should investors view CareDx Inc (CDNA)? 2022/12/29 14:16:00 US Post News
CareDx Inc (NASDAQ:CDNA) closed Wednesday at $11.09 per share, up from $10.88 a day earlier. While CareDx Inc has overperformed by 1.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CDNA fell by -74.94%, with highs and lows ranging from $47.82 to $10.68, whereas the simple […]
CareDx Inc (NASDAQ:CDNA) Shares Plunges -3.35% In A Week – But Can It Keep Rising? 2022/11/04 16:00:00 Marketing Sentinel
In recent trading session, CareDx Inc (NASDAQ:CDNA) saw 0.52 million shares changing hands at last check today with its beta currently measuring 1.01. Company’s recent per share price level of $16.51 trading at -$2.22 or -11.85% at last check today assigns it a market valuation of $979.58M. That most recent trading price of CDNA’s stock … CareDx Inc (NASDAQ:CDNA) Shares Plunges -3.35% In A Week – But Can It Keep Rising? Read More »
CareDx, Inc PT Lowered to $32 at Craig-Hallum 2022/11/04 13:32:11 Investing.com
https://www.investing.com/news/pro/caredx-inc-pt-lowered-to-32-at-craighallum-432SI-2933203
CareDx To Participate in Upcoming Investor Conferences 2022/11/04 11:00:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences. CareDx’s management is scheduled to present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9th, 2022, at 1:25 PM ET. To listen
CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2022 Results - Earnings Call Transcript 2022/11/04 02:52:10 Seeking Alpha
CareDx, Inc (NASDAQ:NASDAQ:CDNA) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO…
CareDx, Inc 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:CDNA) 2022/11/03 22:13:12 Seeking Alpha
The following slide deck was published by CareDx, Inc in conjunction with their 2022 Q3 earnings call.
CareDx, Inc.: CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society 2022/09/12 12:22:00 Finanz Nachrichten
Over 25 Abstracts Highlight Value of AlloSure and AlloSeq cfDNA CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differ…
CareDx''s Return On Capital Employed Insights 2022/08/17 13:57:48 Benzinga
Benzinga Pro data, CareDx (NASDAQ: CDNA ) reported Q2 sales of $80.63 million. Earnings fell to a loss of $21.70 million, resulting in a 10.43% decrease from last quarter. CareDx collected $79.42 million in revenue during Q1, but reported earnings showed a $19.65 million loss. Why Is ROCE Significant? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
CareDx: Best Near Cap-Gain Health Diagnostics Prospect (NASDAQ:CDNA) 2022/08/08 12:04:04 Seeking Alpha
We discuss why CareDx (CDNA) is now a better buy to help build your portfolio’s near-term capital value. Click here to read more.
CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2022 Results - Earnings Call Transcript 2022/08/07 15:34:01 Seeking Alpha
CareDx, Inc. (NASDAQ:NASDAQ:CDNA) Q2 2022 Results Conference Call August 04, 2022 04:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference…